Login / Signup

Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments.

Matea PavicQiyu LiStephanie JuritzArunas GircysAnita WolferUlrich-Peter Rohr
Published in: Oncology (2024)
Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.
Keyphrases
  • decision making
  • early stage
  • papillary thyroid
  • drug administration
  • palliative care
  • squamous cell
  • transcription factor
  • clinical practice
  • lymph node metastasis
  • childhood cancer
  • young adults